SHILPAMED.NSSHILPAMED.NSNSE
Loading
Year-over-year earnings per share growth rate
3Y CAGR
-72.6%/yr
vs -31.7%/yr prior
Acceleration
-40.9pp
Decelerating
Percentile
P44
Within normal range
vs 3Y Ago
0x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 1.33% |
| Q3 2025 | -6.25% |
| Q2 2025 | 224.32% |
| Q1 2025 | -54.46% |
| Q4 2024 | 77.60% |
| Q3 2024 | 25.34% |
| Q2 2024 | -48.23% |
| Q1 2024 | 432.08% |
| Q4 2023 | 178.95% |
| Q3 2023 | 35.71% |
| Q2 2023 | 115.05% |
| Q1 2023 | -22.37% |
| Q4 2022 | 64.65% |
| Q3 2022 | -2250.00% |
| Q2 2022 | -97.07% |
| Q1 2022 | 201.77% |
| Q4 2021 | -53.88% |
| Q3 2021 | 1189.47% |
| Q2 2021 | -81.55% |
| Q1 2021 | 9.57% |
| Q4 2020 | -83.12% |
| Q3 2020 | -47.40% |
| Q2 2020 | 149.76% |
| Q1 2020 | -37.19% |
| Q4 2019 | 8.35% |
| Q3 2019 | 222.80% |
| Q2 2019 | -34.13% |
| Q1 2019 | 91.50% |
| Q4 2018 | -70.46% |
| Q3 2018 | 25.42% |
| Q2 2018 | 4.82% |
| Q1 2018 | 85.85% |
| Q4 2017 | -49.64% |
| Q3 2017 | 51.99% |
| Q2 2017 | -36.03% |
| Q1 2017 | 113.30% |
| Q4 2016 | -59.15% |
| Q3 2016 | 158.85% |
| Q2 2016 | -61.05% |
| Q1 2016 | 36.94% |